VCEL
NASDAQ
$45.88
Vericel Corp (VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $57.14 (+24.54%)
Market Cap
$2.38B
PEG Ratio
0.18
EPS 5Y CAGR
+35.66%
FCF 5Y CAGR
+20.46%
Price Chart
Valuation
Market Cap$2.38B
P/E109.92
Forward P/E98.04
PEG0.18
P/S8.06
P/B6.81
Profitability
Total Revenue (TTM)$292M
Gross Profit (TTM)$219M
EBITDA$28M
Profit Margin-9.2%
Operating Margin-11.8%
EPS$0.43
Financial Health
Free Cash Flow Yield1.99%
Growth & Risk
EPS 5Y CAGR+35.66%
Revenue 5Y CAGR+17.77%
FCF 5Y CAGR+20.46%
Beta (5Y)1.13
Sharpe Ratio0.65